Canada will have a pilot program for international travelers for the option to shorten the 14-day self-isolation period for COVID-19 to about 48 hours if a traveler receives a negative COVID-19 test result at one of two border crossings in the province.
If the test comes back negative, travelers will be allowed to leave their place of quarantine as long as they remain in Alberta for the first 14 days and commit to getting a second test on Day 6 or 7 after arrival, at a community pharmacy participating in the pilot program.
If the results are positive the program will be expanded to other Canadian cities.
Abbott Labs ID NOW
As a world leader in point-of-care diagnostics, Abbott first introduced in 2014, the ID NOW system. It is the leading molecular point-of-care platform for Influenza A & B, Strep A and RSV testing in the U.S. ID NOW is a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. Its unique isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing clinicians to make evidence-based clinical decisions during a patient visit.
The gold standard for diagnosing covid-19 is a PCR test. Your nasal passages are swabbed and the sample is sent through a polymerase chain reaction (PCR). PCR amplifies any viral genetic material to make the test more accurate. False negatives are usually very rare, close to only about 2%. Early studies in the pandemic reported false negative rates as high as 37% for nasal swabs, but these problems appear to have been fixed.
Abbott claims ID NOW test has a false negative rate of 5.3%. Other studies have show false negatives as high as 75%. Abbot has BinaxNOW which could deliver results in under 15 minutes and a false negative rate of just 2.9%.
Abundant Fast, Accurate COVID Tests Can Reduce the Societal Burden
In the first week of October, the U.S. Food and Drug Administration gave emergency use authorization for scientists at UCLA Health to begin using a new method of COVID-19 detection using sequencing technology called SwabSeq. The method is capable of testing thousands of samples for coronavirus at the same time, producing accurate, individual results in 12 to 24 hours. SwabSeq adds a unique molecular bar code to each sample in the first step of its processing. The samples are then combined in a sequencer and the bar codes allow for the identification of which specific sample has the virus. The underlying technology of SwabSeq can be applied to any type of sample collection, such as a nasopharyngeal, oropharyngeal or saliva test.
SOURCES – UCLA, Abbott, CBC, Calgary International Airport
Written By Brian Wang, Nextbigfuture.com
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.